bz371a
Erectile Dysfunction Following Radical Prostatectomy
Biozeus Biopharmaceutical S.A.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Erectile Dysfunction Following Radical Prostatectomy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tadalafil Surgical Outcomes Research Centre (SOuRCe) | Phase 4 | BB |
Sildenafil The Netherlands Cancer Institute | Phase 4 | BB |
BAY38-9456 Bayer | Phase 4 | BB |
Indocyanine Green Ankara University | Phase 4 | BB |
Ningmitai Xintian Pharmaceutical | Phase 4 | BB |
View all 38 →
Same molecule, other indications
bz371a is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →